These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. Hainsworth JD; Johnson DH; Greco FA J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284 [TBL] [Abstract][Full Text] [Related]
6. The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary. van der Gaast A; Verwij J; Planting AS; Stoter G; Henzen-Logmans SC J Cancer Res Clin Oncol; 1996; 122(3):181-85. PubMed ID: 8601568 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. Hainsworth JD; Lennington WJ; Greco FA J Clin Oncol; 2000 Feb; 18(3):632-5. PubMed ID: 10653878 [TBL] [Abstract][Full Text] [Related]
8. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. Motzer RJ; Rodriguez E; Reuter VE; Bosl GJ; Mazumdar M; Chaganti RS J Clin Oncol; 1995 Jan; 13(1):274-82. PubMed ID: 7799031 [TBL] [Abstract][Full Text] [Related]
9. Poorly differentiated carcinoma and germ cell tumors. Hainsworth JD; Greco FA Hematol Oncol Clin North Am; 1991 Dec; 5(6):1223-31. PubMed ID: 1663941 [TBL] [Abstract][Full Text] [Related]
10. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site. Hainsworth JD; Dial TW; Greco FA Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881 [TBL] [Abstract][Full Text] [Related]
11. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Hainsworth JD; Johnson DH; Greco FA Ann Intern Med; 1988 Sep; 109(5):364-71. PubMed ID: 2841895 [TBL] [Abstract][Full Text] [Related]
12. Immunohistological studies in five patients with unknown primary carcinomas and poorly differentiated neoplasms. Greenberg BR Ann Clin Lab Sci; 1989; 19(3):175-83. PubMed ID: 2658727 [TBL] [Abstract][Full Text] [Related]
18. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site. Hainsworth JD; Johnson DH; Greco FA Cancer; 1991 Jan; 67(1 Suppl):310-4. PubMed ID: 1984833 [TBL] [Abstract][Full Text] [Related]
19. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site. Greco FA; Hainsworth JD Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278 [TBL] [Abstract][Full Text] [Related]
20. Identification of types and primary sites of malignant tumors by examination of exfoliated tumor cells in serous fluids. Comparison with the diagnostic accuracy on small histologic biopsies. Spieler P; Gloor F Acta Cytol; 1985; 29(5):753-67. PubMed ID: 2996273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]